retatrutide clinical trial results 2025 for Weight Loss: What It Is, How It Works & Side Effects Retatrutide produces up to 30.3%
Description
Seven additional trials will report throughout 2026

2024;6:ojae069

Retatrutide is an investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously currently progressing through Phase 3 clinical trials

Novo Nordisk Press Release: Zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes presented at ADA 2026

Ma R-L, Deng Y, Wang Y-F, et al

We prefer oral or SC routes rather than IV drips because IVs can be unpredictable in the clinic and expensive
